期刊文献+

注射用重组人凝血因子Ⅷ大鼠单次与反复给药毒性研究 被引量:1

Acute and sub-chronnic toxicity studies of recombinant human coagulation factor Ⅷ for injection in rats
原文传递
导出
摘要 目的进行注射用重组人凝血因子Ⅷ的大鼠药物安全性评价,为临床安全用药提供参考信息。方法急性毒性试验对SD大鼠采用最大给药剂量法(66 460 IU/kg·bw),观察给药后大鼠出现的毒性反应。反复给药毒性试验设50、250和1 250 IU/kg·bw 3个给药组(分别相当于临床剂量的1、5和25倍)及溶剂对照组,连续给药30 d,停药后恢复期观察4周。结果急性毒性试验,动物临床观察结果、体重、大体解剖结果,给药组与对照组相比未见任何显著性差异。30 d连续给药试验中,出现与凝血因子Ⅷ抑制物相关的临床症状,如APTT延长、出血和A/G降低等,未发现与给药明确相关的毒性病理改变,未见明显与给药相关的延迟或蓄积毒性。结论 SD大鼠单次静脉注射注射用重组人凝血因子Ⅷ的最大耐受剂量大于66 460 IU/kg·bw;30 d重复给药未见明显毒性反应剂量(NOAEL)为1 250 IU/kg·bw。本试验结果为该品的临床应用提供了参考数据。
出处 《毒理学杂志》 CAS CSCD 2018年第4期301-304,共4页 Journal of Toxicology
基金 国家自然科学基金(81773996) 重大新药创制专项(2013ZX09302302 2012ZX09301002-001-009) 协和青年科研基金(3332015135)
  • 相关文献

参考文献1

二级参考文献34

  • 1CONNOLLY SJ, POGUE J, EIKELBOOM J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range[J]. Circulation, 2008, 118(20): 2029-2037.
  • 2TURPIE AG, BAUER KA, ERIKSSON BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopaedic surgery: a meta-analysis of 4 randomized studies[J]. Arch Intern Med, 2002, 162(16): 1833-1840.
  • 3ERIKSSON BI, LASSEN MR, PENTasaccharide in Hip-FRA- cture Surgery Plus Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a muhicenter, randomized placebo-controlled, double- blind study[J]. Arch Intern Med, 2003, 163(11): 1337-1342.
  • 4TURPIE AG, BAUER KA, CAPRINI JA, et al. Fondaparinux combined with intermittent pneumatic compression vs intermi- ttent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison (APOLLO) [J]. J Thromb Haemost, 2007, 5(9): 1854-1861.
  • 5AGNELLI G, BERGQVIST D, COHEN AT, et al. Randomized clinical trim of postoperative fondaparinux versus perioperative daheparin for prevention of venous thromboembolism in high-risk abdominal surgery[J]. Br J Surg, 2005, 92(10) : 1212-1220.
  • 6COHEN AT, DAVIDSON BL, GALLUS AS, et ol. Efficacy and safety of fondaparinux for the prevention of venous thromboem- bolism in older acute medical patients: randomized placebo controlled triM[J]. BMJ, 2006, 332(7537): 325-329.
  • 7DECOUSUS H, PRANDONI P, MISMETYI P, et al. Fondaparinux for the treatment of superficial-vein thrombosis in the legs[J]. N Engl J Med, 2010, 363(13) : 1222-1232.
  • 8BULLER HR, DAVIDSON BL, DECOUSUS H, et ol. Fon- daparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized triM[J]. Ann Intern Med, 2004, 140(11) : 867-873.
  • 9BULLER HR, DAVIDSON BL, DECOUSUS H, et al. Sub- cutaneous fondaparinux versus intravenous unfractionated heparin in the treatment of pulmonary embolism[J]. N Engl J Med, 2003, 349(18) : 1695-1702.
  • 10YUSUF S, MEHTA SR, CHROLAVICIUS S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes[J]. N Engl J Med, 2006, 354(14): 1464-1476.

共引文献6

同被引文献13

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部